|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.03.26 - 01:33
|
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering (GlobeNewswire EN)
|
|
|
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions....
|
|
|
|
|
|
|
12.03.26 - 12:03
|
Indivior Announces Proposed Convertible Senior Notes Offering (GlobeNewswire EN)
|
|
|
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes....
|
|
|
|
|
|
|
11.03.26 - 14:03
|
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder (GlobeNewswire EN)
|
|
|
RICHMOND, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals (Nasdaq: INDV) today announced findings from a new real-world evidence, retrospective observational study published in Frontiers in Public Health showing that adherence to SUBLOCADE® (extended-release buprenorphine), a monthly injectable, is associated with meaningfully lower healthcare utilization and medical costs among commercially insured patients with opioid use disorder (OUD). These outcomes were more favorable compared to both patients adherent to other medications for OUD (MOUD) and to those who were nonadherent to MOUD....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.01.26 - 20:24
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 28.01.2026 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 28.01.2026.
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.01.2026.
ISIN Name
CA31773B5018 FINCANNA CAPITAL CORP.
CA74040N1069 PREDICTMEDIX AI INC.
GB00BN4HT335 INDIVIOR PLC DL 0,50
NO0013643114 HAWK IN.SOF. 25/30 FLR 2
US5860011098 SOHO HOUSE+CO A DL-,01
XS2447539060 SAG.E.MTN NL 22/26 MTN
XS2493887264 PREEM HLDGS 22/27...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
